{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:32:00Z","timestamp":1787923920162,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00441114"],"award-info":[{"award-number":["RS-2024-00441114"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.biopha.2024.117674","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:29:21Z","timestamp":1731446961000},"page":"117674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lower hepatotoxicity risk in Xelaglifam, a novel GPR40 agonist, compared to Fasiglifam for type 2 diabetes therapy"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3966-4890","authenticated-orcid":false,"given":"Jongmin","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haengjin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yearin","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ah","family":"Gim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Mi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Tae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchul","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-8361","authenticated-orcid":false,"given":"Yun Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5266-1722","authenticated-orcid":false,"given":"Sang Geon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6928","key":"10.1016\/j.biopha.2024.117674_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.biopha.2024.117674_bib2","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2024.117674_bib3","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1007\/s00125-012-2650-x","article-title":"G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1","volume":"55","author":"Ferdaoussi","year":"2012","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbrc.2005.07.042","article-title":"Role of GPR40 in fatty acid action on the beta cell line INS-1E","volume":"335","author":"Shapiro","year":"2005","journal-title":"Biochem Biophys. Res Commun."},{"issue":"3","key":"10.1016\/j.biopha.2024.117674_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1463-1326.2011.01525.x","article-title":"GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes","volume":"14","author":"Araki","year":"2012","journal-title":"Diabetes Obes. Metab."},{"issue":"9824","key":"10.1016\/j.biopha.2024.117674_bib6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","article-title":"TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"379","author":"Burant","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.biopha.2024.117674_bib7","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/dom.13004","article-title":"Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study","volume":"19","author":"Marcinak","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2024.117674_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40264-018-0642-6","article-title":"Liver Safety of Fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience [published correction appears in drug Saf. 2018 Dec;41(12):1431-1437","volume":"41","author":"Marcinak","year":"2018","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"4","key":"10.1016\/j.biopha.2024.117674_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117674_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/toxsci\/kfx040","article-title":"Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury","volume":"163","author":"Otieno","year":"2018","journal-title":"Toxicol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2024.117674_bib12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1124\/dmd.115.064121","article-title":"Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib13","first-page":"50","article-title":"Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury","volume":"157","author":"Wolenski","year":"2017","journal-title":"Toxicol. Sci."},{"issue":"517","key":"10.1016\/j.biopha.2024.117674_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5516","article-title":"Reproducing human and cross-species drug toxicities using a Liver-Chip","volume":"11","author":"Jang","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"8","key":"10.1016\/j.biopha.2024.117674_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1021\/tx300091x","article-title":"In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs","volume":"25","author":"Thompson","year":"2012","journal-title":"Chem. Res Toxicol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117674_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nmeth.1186","article-title":"Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors","volume":"5","author":"Romanov","year":"2008","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/03602532.2011.605791","article-title":"Metabolic activation in drug-induced liver injury","volume":"44","author":"Leung","year":"2012","journal-title":"Drug Metab. Rev."},{"issue":"12","key":"10.1016\/j.biopha.2024.117674_bib18","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1124\/dmd.109.028860","article-title":"Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins","volume":"37","author":"Usui","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2024.117674_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.taap.2017.09.013","article-title":"Long-enduring primary hepatocyte-based co-cultures improve prediction of hepatotoxicity","volume":"336","author":"Novik","year":"2017","journal-title":"Toxicol. Appl. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2024.117674_bib20","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0192623316642527","article-title":"Characterizing \"adversity\" of pathology findings in nonclinical toxicity studies: results from the 4th ESTP international expert workshop","volume":"44","author":"Palazzi","year":"2016","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117674_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/0192623312448935","article-title":"Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes--conclusions from the 3rd International ESTP expert workshop","volume":"40","author":"Hall","year":"2012","journal-title":"Toxicol. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117674_bib22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0192623310373778","article-title":"Hepatic enzyme induction: histopathology","volume":"38","author":"Maronpot","year":"2010","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117674_bib23","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1177\/0192623310386499","article-title":"Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system","volume":"38","author":"Thoolen","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2024.117674_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9737920","article-title":"Key challenges and opportunities associated with the use of in vitro models to detect human dili: integrated risk assessment and mitigation plans","volume":"2016","author":"Atienzar","year":"2016","journal-title":"Biomed. Res Int"},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/clpt.2012.43","article-title":"A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes","volume":"92","author":"Leifke","year":"2012","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/dmd.111.040758","article-title":"In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans","volume":"40","author":"Dawson","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2024.117674_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1590-8658(02)80033-0","article-title":"Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease","volume":"34","author":"Guicciardi","year":"2002","journal-title":"Dig. Liver Dis."},{"issue":"10","key":"10.1016\/j.biopha.2024.117674_bib29","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.117674_bib30","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"issue":"31","key":"10.1016\/j.biopha.2024.117674_bib31","article-title":"Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury","volume":"98","author":"Ma","year":"2019","journal-title":"Med. (Baltim. )"},{"issue":"8","key":"10.1016\/j.biopha.2024.117674_bib32","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00204-017-2002-1","article-title":"Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury","volume":"91","author":"Proctor","year":"2017","journal-title":"Arch. Toxicol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117674_bib33","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3390\/ijms22062954","article-title":"Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges","volume":"22","author":"Jee","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem. Biol. Inter."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.biopha.2024.117674_bib36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1124\/dmd.107.019901","article-title":"Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies","volume":"36","author":"Joss\u00e9","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.biopha.2024.117674_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2131\/fts.7.153","article-title":"Usefulness of HepaRG cells in the mitochondrial function assay for the estimation of potential risk of idiosyncratic drug-induced liver injury","volume":"7","author":"Goda","year":"2020","journal-title":"Funda Toxicol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2024.117674_bib38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jat.3090","article-title":"HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening","volume":"35","author":"Wang","year":"2015","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.biopha.2024.117674_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.730008","article-title":"Human three-dimensional hepatic models: cell type variety and corresponding applications","volume":"9","author":"Xu","year":"2021","journal-title":"Front Bioeng. Biotechnol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117674_bib40","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00204-020-02763-w","article-title":"The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development","volume":"94","author":"Walker","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117674_bib41","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfv152","article-title":"Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays","volume":"147","author":"Shah","year":"2015","journal-title":"Toxicol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.117674_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aar4666","article-title":"Evaluating biological activity of compounds by transcription factor activity profiling","volume":"4","author":"Medvedev","year":"2018","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/toxsci\/kfx231","article-title":"The identification of pivotal transcriptional factors mediating cell responses to drugs with drug-induced liver injury liabilities","volume":"162","author":"Shah","year":"2018","journal-title":"Toxicol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.117674_bib44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117674_bib45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.amjms.2017.01.019","article-title":"AP-1 expression and its clinical relevance in immune disorders and cancer","volume":"353","author":"Trop-Steinberg","year":"2017","journal-title":"Am. J. Med Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.22710","article-title":"c-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: multiple roles in multiple steps.","volume":"49","author":"Kodama","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2024.117674_bib47","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/s41418-018-0239-8","article-title":"The transcription factor c-Jun\/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression","volume":"26","author":"Schulien","year":"2019","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.biopha.2024.117674_bib48","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jhep.2020.01.023","article-title":"NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly","volume":"72","author":"He","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117674_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.642500","article-title":"Latent cytomegalovirus reactivation in patients with liver failure: a 10-year retrospective case-control study, 2011-2020","volume":"11","author":"Yang","year":"2021","journal-title":"Front Cell Infect. Microbiol"},{"issue":"1","key":"10.1016\/j.biopha.2024.117674_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.109.151233","article-title":"Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones","volume":"330","author":"Kaimal","year":"2009","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2024.117674_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.apha.2018.12.001","article-title":"Mechanisms of idiosyncratic drug-induced liver injury","volume":"85","author":"Uetrecht","year":"2019","journal-title":"Adv. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224015609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224015609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:00:45Z","timestamp":1787922045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224015609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":51,"alternative-id":["S0753332224015609"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117674","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower hepatotoxicity risk in Xelaglifam, a novel GPR40 agonist, compared to Fasiglifam for type 2 diabetes therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117674"}}